Seres Therapeutics

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer to Advance Protein Degradation Platform

2 months ago

• Kymera Therapeutics has appointed Noah Goodman, MBA, as Chief Business Officer to lead business development strategy for its targeted protein degradation platform focused on immunological diseases. • Goodman brings extensive experience from leadership roles at Chroma Medicine, nChroma Bio, Cadent Therapeutics, and Seres Therapeutics, where he specialized in business development and strategic partnerships. • Kymera is pioneering oral small molecule degrader medicines with "biologics-like activity" and has already advanced its first protein degrader into clinical trials for immunological conditions.

Biotech Leadership Shuffle Continues as Industry Navigates Transformation in Q2 2025

2 months ago

• Novo Nordisk undergoes significant executive restructuring following the departure of EVP Camilla Sylvest, with rare disease leader Ludovic Helfgott taking over expanded commercial strategy responsibilities. • Galapagos faces major leadership transition as CEO Paul Stoffels announces retirement plans while CFO Thad Huston departs, amid the company's ongoing transformation into a cell therapy-focused biotech. • Multiple biotechs including Hansa Biopharma, Creyon Bio, and Sutro Biopharma appoint new CEOs as the industry continues strategic realignment efforts. • Emerging companies across oncology, rare diseases, and AI-driven drug development strengthen their leadership teams with experienced executives from major pharmaceutical companies.

Microbiome Therapeutics Pipeline Expands with 180+ Novel Therapies in Development Across 140 Companies

3 months ago

• The microbiome therapeutics landscape shows remarkable growth with over 140 companies actively developing 180+ pipeline drugs, spanning various disease areas and therapeutic approaches. • Recent clinical advances include promising results from MaaT Pharma's Phase 3 ARES study for GI-aGvHD and Vedanta Biosciences' Phase 2 CONSORTIUM study of VE303 for recurrent C. difficile infection. • Multiple innovative approaches are being pursued, including live biotherapeutic products, with companies like Microbiotica's MB097 showing potential in enhancing immunotherapy responses in cancer treatment.

Tech Innovations and Strategic Partnerships Highlight CES 2025

5 months ago

At CES 2025, Tuya Smart showcased AI-driven innovations and strategic partnerships, while other companies like Mativ Holdings and Vision Marine Technologies announced significant advancements in their respective fields. The event also highlighted developments in healthcare, biotechnology, and the energy sector, showcasing the latest in technology and strategic collaborations.

MaaT013 Shows Promise in Phase 3 Trial for GI-aGvHD

5 months ago

• MaaT Pharma's MaaT013 met its primary endpoint in the Phase 3 ARES trial, demonstrating a 62% gastrointestinal overall response rate (GI-ORR) in patients with GI-aGvHD. • The study showed a 54% estimated 12-month overall survival rate, with responders at day 28 exhibiting a significantly higher survival rate of 67% compared to non-responders. • MaaT Pharma plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in mid-2025 for MaaT013 as a third-line treatment. • The ARES trial represents the first positive pivotal clinical study for a microbiome-based approach in GI-aGvHD, potentially offering a new treatment option for patients.

RBX2660 Receives FDA Breakthrough Therapy Designation for Recurrent C. diff Infection

5 months ago

• RBX2660, a microbiota restoration therapy developed by Rebiotix and acquired by Ferring, has been granted Breakthrough Therapy Designation by the FDA for recurrent Clostridioides difficile infection. • The drug aims to restore gut microbiome balance by transplanting live, human-derived microbes into the intestinal tract, offering a potential alternative to antibiotic treatments. • Phase 3 trial data (PUNCH CD 3) demonstrated preliminary positive efficacy in reducing C. diff recurrence, positioning RBX2660 as a frontrunner in live microbiota-based therapies. • RBX2660 has already been granted orphan drug and fast-track status, potentially expediting its path to market for patients with limited treatment options.

Seres Therapeutics' SER-155 Shows Promise in Reducing Bloodstream Infections Post-Stem Cell Transplant

6 months ago

• Seres Therapeutics' SER-155 receives Breakthrough Therapy designation from the FDA for reducing bloodstream infections (BSIs) in allo-HSCT patients. • Phase 1b trial data showed a 77% relative risk reduction in BSIs with SER-155, along with decreased antibiotic use and febrile neutropenia. • Biomarker data from the study indicate that SER-155 promotes epithelial barrier integrity and reduces systemic inflammation. • Seres is seeking a strategic partner to advance SER-155's development and explore its potential in other high-risk patient populations.

Tulisokibart Shows Promise in Treating Moderate to Severe Ulcerative Colitis

8 months ago

• A Phase 2 trial of tulisokibart, an anti-TL1A monoclonal antibody, demonstrated superior efficacy compared to placebo in inducing clinical remission in patients with moderate to severe ulcerative colitis. • The study utilized a genetic-based diagnostic test to identify patients more likely to respond to tulisokibart, showing improved remission rates in this subgroup. • Tulisokibart modulates inflammation and the body's anti-inflammatory mechanisms, offering a novel approach compared to existing IBD treatments that can exacerbate inflammation. • The safety profile of tulisokibart appeared comparable to placebo, with similar rates of adverse events, supporting its potential as a valuable new treatment option.